Aclaris Therapeutics (ACRS) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.12

Estimate

-$0.16

Surprise

+25.8%

Revenue (period 2026-09-30)

$1.5M

Score today

4.7/10

Revenue source: xbrl.

Aclaris Therapeutics (ACRS) reported a narrower loss than forecast — adjusted EPS of -$0.12 against the -$0.16 estimate (a 25.8% beat on a still-unprofitable quarter).

• Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update — fiscal.ai, 2026-11-05
• Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate — benzinga, 2026-11-05

TrendMatrix currently rates ACRS Sell at 4.7/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +25.8% surprise compares with a +4.7% four-quarter average. Next scheduled report: 2027-02-25.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$3.90

Price target

$9.02

Stop

$3.63

Upside to target

+131.3%

Reward-to-risk

8.8:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$604.4M

P/E (fwd)

-5.4

52-week range

$2.10–$6.60

Off 52-week high

40.9%

RSI (14)

66

Volume vs avg

1.27×

Score today

4.7/10